Ação Cidara Therapeutics (CDTX)
Empresa de capital aberto. Aqui estão o preço, um resumo do negócio e o que vale a pena saber sobre Cidara Therapeutics em setembro 2026.
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Desempenho de crescimento em seis meses
Resumo do desempenho da ação
Avaliação dos analistas
Analysts suggest holding CIDARA's stock as its target price is slightly lower than the current price.
Saúde financeira
Cidara Therapeutics is showing strong financial performance, highlighted by solid cash flow and book value.
Veja mais ações baixando o app GRÁTIS
Leva só 60 segundos.
Por que investir com a Nemo?
Zero comissão
Negocie ações, ETFs e muito mais sem comissão. Fique com uma parte maior dos seus retornos.
Confiável e regulamentado
Parte do grupo Exinity desde 2015, atendendo a mais de um milhão de clientes em todo o mundo.